Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Inclusion Criteria: * Current diagnosis of small bowel or colonic Crohn's disease as defined by histological and endoscopic criteria. * Males or females ages 11-17 years. * Crohn's disease in remission as defined by a Pediatric Crohn's Disease Activity Index (PCDAI) \< 10 * Patients on maintenance doses of aminosalicylates, 6-MP and/or Azathioprine for at least 2 months. * Procurement of written informed consent signed by the subject's legal guardian and study investigator(s) and patient assent. Exclusion Criteria: * Patients with documented intestinal stricture. * Patients with signs of symptoms of systemic or intestinal infection. * Antibiotic use the previous 1 month. * Probiotic use in the previous 2 months (excluding yogurt). * Use of the following medications; Methotrexate, Cyclosporine, Tacrolimus and Infliximab. * Patients with diagnosis of other co-morbid diseases such as heart disease, renal disease, immunodeficiency, diabetes, or thyroid disease. * Patients with indwelling catheters. * Patients with short bowel syndrome * Positive urine pregnancy test for female subjects